Eversana taps Cornerstone’s research services, expands insights offering

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/Chainarong Prasertthai)
(Image: Getty/Chainarong Prasertthai)

Related tags: Eversana, Data, Data management, acquisition

Eversana acquires Cornerstone Research Group with an aim to expand its portfolio of Health Economics and Outcomes Research (HEOR).

Canada-based Cornerstone Research Group is a provider of Health Economics and Outcomes Research (HEOR) services, working with pharmaceutical and medical device companies.

Through the acquisition, the financial details of which were not disclosed, Eversana aims to add these capabilities in its portfolio on a global scale.

More specifically, upon completion of the transaction, the acquiring company will add a range of services in its offering, including economic modeling, evidence synthesis, value communication, and reimbursement strategies across all stages of drug development.

The transaction is expected to close in the coming quarter, with Cornerstone’s executives, Chris Cameron, Daniel Grima, and Melissa Thompson being appointed into leadership roles at Eversana.

Jim Lang, CEO of Eversana, told us that the addition of Cornerstone “will strengthen the company’s HEOR capabilities, further solidify depth and breadth of expertise,” ​as well as help Eversana expand its global footprint.

According to Lang, Cornerstone’s team consists of “experts in reimbursement strategy, evidence synthesis, economic modeling, data analytics and value communication.” 

The acquisition will allow Eversana to answer market demands coming from pharmaceutical companies that “face strong pressures to quickly assess and quantify both the direct and indirect value of their in-market products and development pipeline,”​ the CEO said in a statement.

“By adding a strong health economics and outcomes capability to our integrated commercial platform, we can now conceptualize, deliver and measure value at every stage of the product lifecycle from clinical trials to ongoing patient adherence,” ​Lang added.

“The need for evidence-based research has never been greater than in today’s pharmaceutical industry,” ​Melissa Thompson commented on her side.

Continuous expansion

The company has been taking significant steps to boost its growth over the past year, with the most recent being the opening of its fourth distribution center in the US​, announced earlier in October, with an aim to answer an increased demand in logistics services, according to Danny Williams, president of Channel Management at Eversana.

Williams also told us then that the company has seen an increase in demand for storage and distribution of temperature-sensitive products, a market need that it expects to address through the recently-established partnership​ with the cold-chain logistics services provider, Cryoport.

Earlier this year, Eversana also announced an expansion of its footprint in Asia, with the opening of four new offices​ in China, Japan, Singapore, and India.

Related news

Show more

Related products

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q² Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more